Gangolli Julian S 4
4 · Revance Therapeutics, Inc. · Filed May 3, 2024
Insider Transaction Report
Form 4
Gangolli Julian S
Director
Transactions
- Award
Common Stock
2024-05-01+15,000→ 45,106 total - Award
Stock Option (Right to buy)
2024-05-01+23,458→ 23,458 totalExercise: $3.79Exp: 2034-04-30→ Common Stock (23,458 underlying)
Footnotes (2)
- [F1]Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
- [F2]The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.